NRXP Stock Price, NRx Pharmaceuticals, . Quote, Chart

Market Summary

USD3.520.00

Delayed

0.00%

NRXP Stock Price

View Fullscreen

NRXP RSI Chart

NRXP Valuation

Market Cap

37.2M

Price/Earnings (Trailing)

-1.45

Price/Sales (Trailing)

75.21

EV/EBITDA

-0.82

Price/Free Cashflow

-1.93

NRXP Price/Sales (Trailing)

NRXP Profitability

EBT Margin

-8047.37%

Return on Equity

170.14%

Return on Assets

-676.85%

Free Cashflow Yield

-51.78%

NRXP Fundamentals

NRXP Revenue

Revenue (TTM)

494.0K

Rev. Growth (Yr)

37.04%

Rev. Growth (Qtr)

-53.9%

NRXP Earnings

Earnings (TTM)

-25.6M

Earnings Growth (Yr)

40.86%

Earnings Growth (Qtr)

-50.69%

Breaking Down NRXP Revenue

Last 7 days

15.8%

Last 30 days

-15.8%

Last 90 days

-25.3%

Trailing 12 Months

-48.2%

How does NRXP drawdown profile look like?

NRXP Financial Health

Current Ratio

0.18

NRXP Investor Care

Shares Dilution (1Y)

50.13%

Diluted EPS (TTM)

-4.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	310.3K	371.5K	432.8K	494.0K
2022	2.5M	1.4M	0	249.0K
2021	0	0	0	3.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NRx Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 30, 2023	gorovitz aaron	bought	11,196	0.3199	35,000	-
Aug 30, 2023	hurvitz chaim	bought	20,125	0.2875	70,000	-
Aug 23, 2023	javitt jonathan c	bought	33,000	0.33	100,000	chief scientist
Aug 22, 2023	javitt jonathan c	bought	64,400	0.322	200,000	chief scientist
Dec 16, 2022	van voorhees seth	bought	33,000	1.1	30,000	chief financial officer
Dec 16, 2022	willard stephen h	bought	58,500	1.17	50,000	chief executive officer
Dec 14, 2022	javitt jonathan c	gifted	-	-	-300,000	-
Dec 07, 2022	javitt jonathan c	sold	-400,000	1.00	-400,000	-
Nov 30, 2022	javitt daniel c.	sold	-12,700	1.5046	-8,441	-
Nov 29, 2022	javitt daniel c.	sold	-20,651	1.5041	-13,730	-

Which funds bought or sold NRXP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	13,065	13,065	-%
May 15, 2024	STATE STREET CORP	unchanged	-	1,360	53,910	-%
May 15, 2024	MORGAN STANLEY	reduced	-0.87	345	20,739	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-34.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	unchanged	-	1.00	3.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	8.78	1,053	10,113	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	1,460	57,902	-%
May 15, 2024	Royal Bank of Canada	reduced	-99.92	-69,000	-	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	2.00	78.00	-%
May 14, 2024	AdvisorShares Investments LLC	reduced	-4.33	-5,490	290,121	0.05%

Are Funds Buying or Selling NRXP?

Are funds buying NRXP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NRXP

No. of Funds

Unveiling NRx Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 13, 2022	javitt daniel c.	14.6%	9,872,901	SC 13D
Jun 17, 2022	javitt jonathan c	22.3%	14,868,329	SC 13D/A
Jun 03, 2022	javitt jonathan c	22.3%	14,868,329	SC 13D

Recent SEC filings of NRx Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 19, 2024	424B5	Prospectus Filed
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	424B5	Prospectus Filed
Apr 15, 2024	424B3	Prospectus Filed
Apr 15, 2024	424B3	Prospectus Filed
Apr 15, 2024	8-K	Current Report

Peers (Alternatives to NRx Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

NRx Pharmaceuticals, Inc. News

Latest updates

NRx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-53.9%	481,000	1,043,333	1,605,667	2,168,000	351,000	175,500	-	2,020,000	2,844,500	3,669,000
Operating Expenses	36.1%	5,998,000	4,406,000	5,808,000	8,188,000	9,435,000	9,888,500	9,600,000	15,705,000	52,975,000	20,099,000
S&GA Expenses	-100.0%	-	1,872,000	2,494,000	4,065,000	5,785,000	5,432,000	6,642,000	10,222,000	51,641,000	13,823,000
R&D Expenses	-31.0%	1,748,000	2,534,000	3,314,000	3,873,000	3,650,000	4,456,500	2,958,000	5,483,000	6,413,000	6,276,000
EBITDA Margin	0%	-80.22	-80.22	-91.84	-106	-128	-159	-66.99	-36.79	-25.36	-
Interest Expenses	367.5%	374,000	80,000	40,000	-	-	-	-	3,000	2,500	5,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-30,407,181	-37,049,331
EBT Margin	0%	-80.47	-80.47	-91.86	-107	-128	-159	-67.00	-36.80	-25.36	-
Net Income	-50.7%	-6,528,000	-4,332,000	-6,062,000	-8,717,000	-11,039,000	-10,241,000	-6,982,000	-13,448,000	-30,407,500	-37,049,000
Net Income Margin	15.0%	-51.90	-61.03	-83.33	-105	-120	-159	-63.27	-32.04	-25.36	-
Free Cashflow	-15.0%	-3,671,000	-3,192,000	-4,564,000	-7,812,000	-6,089,000	-8,318,000	-14,791,000	-10,380,000	-11,280,000	-12,014,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-48.2%	4.00	7.00	13.00	20.00	22.00	26.00	25.00	32.00	44.00	33.00	45.00	19.00	14.00	3.00	6.00	6.00	6.00	24.00	42.00	50.00	72.00
Current Assets	-51.4%	3.00	7.00	13.00	20.00	22.00	26.00	25.00	32.00	44.00	33.00	45.00	19.00	14.00	3.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00
Cash Equivalents	-71.3%	1.00	5.00	9.00	15.00	17.00	20.00	18.00	25.00	40.00	28.00	39.00	13.00	13.00	2.00	1.00	1.00	0.00	1.00	0.00	0.00	0.00
Liabilities	-1.0%	19.00	19.00	19.00	23.00	22.00	18.00	8.00	7.00	12.00	12.00	37.00	58.00	7.00	47.00	3.00	3.00	2.00	6.00	2.00	2.00	2.00
Current Liabilities	-100.0%	-	19.00	19.00	23.00	22.00	16.00	-	-	-	12.00	37.00	58.00	7.00	46.00	0.00	0.00	0.00	2.00	1.00	1.00	0.00
Shareholder's Equity	-28.4%	-15.07	-11.73	-	-	-0.28	7.00	17.00	25.00	32.00	21.00	8.00	-	6.00	2.00	3.00	4.00	4.00	5.00	5.00	5.00	5.00
Retained Earnings	-2.6%	-259	-253	-248	-242	-234	-223	-212	-203	-196	-183	-152	-115	-115	-90.18	0.00	0.00	1.00	-38.40	0.00	0.00	0.00
Additional Paid-In Capital	1.4%	245	241	243	240	234	230	229	229	228	204	161	76.00	122	46.00	3.00	3.00	3.00	34.00	5.00	5.00	5.00
Shares Outstanding	14.0%	10.00	8.00	8.00	8.00	7.00	7.00	7.00	7.00	6.00	6.00	5.00	4.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	30.00	-	34,952,532	-	40,584,788	-	-	-	187	-	-	-	6.00	-	-	-	50.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.0%	-3,671	-3,192	-4,564	-7,812	-6,089	-8,318	-6,266	-14,791	-10,380	-11,280	-12,014	-11,394	-3,015	-406	-1,130	104	-832	-5,011	-52.31	-180	-297
Share Based Compensation	120.1%	242	-1,203	351	544	695	766	541	987	1,334	1,570	1,560	4,283	372	357	191	93.00	89.00	-	-	-	-
Cashflow From Investing	-100.0%	-	1.00	-2.00	2.00	-4.00	1.00	-5.00	-3.00	-3.00	-	-4.00	-3.00	-	-26,211	306	-23.22	25,926	-30,606	8,931	22,179	-508
Cashflow From Financing	135.4%	395	-1,116	-1,501	6,273	2,545	10,122	-28.00	-860	22,980	1.00	37,516	11,512	14,427	980	1,422	620	227	35,691	-8,686	-21,999	797
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	299	-	25,998	-30,990	8,891	22,099	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NRXP Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expense:
Research and development	$ 1,748	$ 3,650
General and administrative	4,250	5,785
Total operating expenses	5,998	9,435
Loss from operations	(5,998)	(9,435)
Other (income) expense:
Interest income	(27)	(156)
Interest expense	230
Change in fair value of convertible note payable	318	1,772
Change in fair value of warrant liabilities	9	(12)
Total other expense	530	1,604
Net loss	(6,528)	(11,039)
Comprehensive (income) loss:
Change in fair value of convertible note attributed to credit risk		(106)
Other comprehensive income		(106)
Comprehensive loss	$ (6,528)	$ (10,933)
Net loss per share:
Basic	$ (0.74)	$ (1.66)
Diluted	$ (0.74)	$ (1.66)
Weighted average common shares outstanding:
Basic	8,852,286	6,647,391
Diluted	8,852,286	6,647,391

NRXP Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,319	$ 4,595
Prepaid expense and other current assets	2,028	2,289
Total current assets	3,347	6,884
Other assets	441	431
Total assets	3,788	7,315
Current liabilities:
Accounts payable	6,265	4,632
Accrued and other current liabilities	5,296	4,714
Accrued clinical site costs	491	524
Convertible note payable and accrued interest	6,779	9,161
Warrant liabilities	26	17
Total liabilities	18,857	19,048
Commitments and Contingencies (Note 8)
Stockholders' deficit:
Preferred stock, value
Common stock, $0.001 par value, 500,000,000 shares authorized; 9,772,672 and 8,391,940 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10	8
Additional paid-in capital	244,599	241,406
Accumulated other comprehensive loss	(3)	(3)
Accumulated deficit	(259,675)	(253,147)
Total stockholders' deficit	(15,069)	(11,733)
Total liabilities and stockholders' deficit	$ 3,788	7,315
Series A Convertible Preferred Stock
Stockholders' deficit:
Preferred stock, value		$ 3

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

0

CEO	Mr. Stephen H. Willard Esq.
WEBSITE	nrxpharma.com
INDUSTRY	Biotechnology

NRx Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for NRx Pharmaceuticals, Inc.? What does NRXP stand for in stocks?

NRXP is the stock ticker symbol of NRx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NRx Pharmaceuticals, Inc. (NRXP)?

As of Fri May 17 2024, market cap of NRx Pharmaceuticals, Inc. is 37.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRXP stock?

You can check NRXP's fair value in chart for subscribers.

What is the fair value of NRXP stock?

You can check NRXP's fair value in chart for subscribers. The fair value of NRx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NRx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NRXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NRx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether NRXP is over valued or under valued. Whether NRx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact NRx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRXP.

What is NRx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NRXP's PE ratio (Price to Earnings) is -1.45 and Price to Sales (PS) ratio is 75.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRXP PE ratio will change depending on the future growth rate expectations of investors.